Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling
Patients with heavily pretreated advanced cancer or with rare tumors are difficult to treat. Molecular profiling (MP) of tumors to identify biomarkers that predict potential outcomes with individual therapies is an emerging strategy to guide treatment decisions. Patients with rare tumors for which s...
Main Authors: | Andrew Dean, Aisling Byrne, Mira Marinova, Ingrid Hayden |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2016/4627214 |
Similar Items
-
Stereotactic body radiation therapy for patients with heavily pretreated liver metastases and liver tumors
by: Rachelle eLanciano, et al.
Published: (2012-03-01) -
Apatinib as Salvage Therapy for Heavily Pretreated SCLC
by: Fangfang LI, et al.
Published: (2018-07-01) -
Pomalidomide-dexamethasone in the management of heavily pretreated multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01) -
Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging
by: Ruben D. Houvast, et al.
Published: (2020-12-01) -
Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies
by: Sabrina Rossi, et al.
Published: (2017-11-01)